Top-News

BioVaxys Technology Aktie News

Aktie
WKN:  A41C58 ISIN:  CA09076M2004 US-Symbol:  BVAXF Branche:  Biotechnologie Land:  Kanada
0,121 €
+0,00 €
0,00%
09:15:13 Uhr
Depot/Watchlist
Marktkapitalisierung *
4,60 Mio. €
Streubesitz
94,03%
KGV
-
Index-Zuordnung
-

BioVaxys Technology News

22.10.25 - PR Newswire
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES PR Newswire
20.10.25 - PR Newswire
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS PR Newswire
14.10.25 - PR Newswire
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
BioVaxys Licensee SpayVac-​for-Wildlife, Inc., Reports Further Positive Single-​Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission ...
29.09.25 - PR Newswire
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA") PR Newswire
16.09.25 - PR Newswire
BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING
BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING PR Newswire
05.09.25 - PR Newswire
BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
BIOVAXYS ANNOUNCES SHARE CONSOLIDATION PR Newswire
15.07.25 - PR Newswire
BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE
BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE PR Newswire
07.07.25 - PR Newswire
BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING
BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING PR Newswire
20.06.25 - PR Newswire
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING PR Newswire
03.06.25 - PR Newswire
BioVaxys Issues Corporate Update
BioVaxys Issues Corporate Update PR Newswire
30.05.25 - PR Newswire
BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000
BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000 PR Newswire
29.05.25 - PR Newswire
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA") PR Newswire
07.05.25 - PR Newswire
BioVaxys and Sona Nanotech Enter Research Collaboration
BioVaxys and Sona Nanotech Enter Research Collaboration PR Newswire
23.04.25 - PR Newswire
BioVaxys und SpayVac-for-Wildlife erweitern Lizenzvereinbarung auf kommerzielle Aquakultur
BioVaxys und SpayVac-​for-Wildlife erweitern Lizenzvereinbarung auf kommerzielle Aquakultur PR Newswire
22.04.25 - PR Newswire
BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture
BioVaxys and SpayVac-​for-Wildlife Expand License Agreement Into Commercial Aquaculture PR Newswire
17.03.25 - PR Newswire
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update PR Newswire
03.03.25 - PR Newswire
BioVaxys Technology Corp. Granted Management Cease Trade Order
BioVaxys Technology Corp. Granted Management Cease Trade Order PR Newswire
13.02.25 - PR Newswire
BioVaxys Announces Application for Management Cease Trade Order
BioVaxys Announces Application for Management Cease Trade Order PR Newswire
17.01.25 - PR Newswire
BioVaxys entwickelt DPX zum Träger der Wahl für mRNA-Impfstoffe - ein Markt, der bis 2030 auf 48.000.000.000 US-Dollar wachsen soll*
BioVaxys entwickelt DPX zum Träger der Wahl für mRNA-​Impfstoffe - ein Markt, der bis 2030 auf 48.000.000.000 US-Dollar wachsen soll* PR Newswire
16.01.25 - PR Newswire
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030* PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »